Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion

Jan 20 (Reuters) - Roche's Genentech said on Tuesday it will more ​than double its initial investment in ‌a biomanufacturing facility in North Carolina to ‌about $2 billion, as the companies look to further boost their $50 billion investment in the U.S.

The facility, based in Holly ⁠Springs, North Carolina ‌is set to be operational by 2029 and will produce ‍next-generation treatments for metabolic conditions, such as obesity.

The investment is expected to support more ​than 2,000 jobs, which includes ‌500 high-wage manufacturing jobs and 1,500 construction jobs, Genentech said, adding that the expansion will further raise production volumes and scale manufacturing capacity within the ⁠facility.

In May last year, ​Genentech invested over $700 million ​in the North Carolina facility, as it looked to expand its ‍presence ⁠in the United States amid President Donald Trump's push for pharma companies ⁠to onshore domestic manufacturing to the U.S.

(Reporting ‌by Gnaneshwar Rajan in Bengaluru; Editing ‌by Shailesh Kuber)